China approves IND application for Everest Medicines novel BTK inhibitor
The Chinese National Medical Products Administration has approved a Phase…
The Chinese National Medical Products Administration has approved a Phase Ib study of Everest Medicines' EVER001, for potential treatment of glomerular diseases.